Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics

Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics Agenda



Plasma Extracellular Vesicles for Cardiovascular Disease

Dominique PV de Kleijn, Professor Experimental Vascular Surgery; Professor Netherlands Heart Institute, University Medical Center Utrecht

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Ischemic heart disease (IHD) comprises 2 entities: Chronic Coronary Syndrome (CCS) and Acute Coronary Syndrome (ACS). Because CCS is associated with 6-8 times increased risk of adverse cardiovascular events like myocardial infarction and death, early recognition of CCS. Blood markers for CCS do not exist, resulting in that 80-90% of chest pain patients undergoing costly imaging do not have CCS. We use plasma extracellular vesicle protein content of vesicles from plasma subfractions as an accurate source for early diagnosis of CCS better than a clinical risk model. Using automated plasma EV fraction analysis and CD9 as an internal marker, we hope with the plasma EV test to reduce the numbers of patients without CCS that are referred for costly imaging.